Biomarker Directed Treatment in Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Registration Number
- NCT01703390
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Brief Summary
This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene expression status suggests better clinical results from historical experience in metastatic colorectal cancer (mCRC). In wild type KRAS mCRC patients treated with either FOLFOX or FOLFIRI in combination with cetuximab the median response rate is approximately 60-65%. Biomarker directed treatment in this study may demonstrate that patients with low ERCC-1 treated with FOLFOX and cetuximab, and those with high ERCC-1 treated with FOLFIRI and cetuximab, will improve response rate to 70-75%. KRAS wild type patients will be treated with 6 cycles of one of the following regimens chosen for optimization based on patient characteristics (primary treatment phase). Patients with ERCC-1 \< 1.7 relative gene expression of ERCC-1 over ß-actin (ERCC-1 low) will be assigned to treatment with mFOLFOX6 in combination with Cetuximab. Patients with ERCC-1 gene expression \> 1.7 relative gene expression of ERCC-1 over over ß-actin (ERCC-1 high) will be assigned to treatment with FOLFIRI in combination with Cetuximab.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 47
1.1 Inclusion criteria for pre-screening phase:
- Untreated advanced metastatic colorectal cancer patients
- Adequate tissue to evaluate for genotyping (10 x 10µm thick formalin fixed paraffin embedded tissue sections and one corresponding HE stained slide or a FFPE tumor block)
1.2 Inclusion criteria for treatment phase:
Patients must fulfill all criteria listed below prior to enrolment in the study:
-
Untreated wild-type KRAS metastatic colorectal cancer
-
Previous adjuvant therapy must have been completed > 6 months before therapy initiation on this study
-
Age >18 years
-
Measureable disease with CT or MRI
-
ECOG performance status of 0-2
-
Adequate organ function
-
Hematologic:
- Absolute neutrophil count > 1,500/µL
- Hemoglobin >9 mg/dl
- Platelet count >100,000 /µl
-
Renal:
- Serum creatinine <1.5 x Upper limit of normal (UPN) or estimated clearance > 30 ml/min
-
Hepatic:
- Serum bilirubin < 1.5 mg/dl
-
- Creatinine clearance below 30 ml/min
- Patients with a history of other malignancies within 2 years prior to study entry, except for adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage localized prostate cancer treated surgically with curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with curative intent.
- Patients with a history of severe cardiac disease; e.g. NYHA Functional Class III or IV heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, or unstable angina.
- Other known co-morbidity with the potential to dominate survival
- Hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the applied drugs
- Pregnant or breast feeding women
- Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ERCC-1 low modifiedFOLFOX6 + Cetuximab modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly ERCC-1 high FOLFIRI + Cetuximab FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles folinic acid (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
- Primary Outcome Measures
Name Time Method Response 5 years Treatment response according to Response Evaluation Criteria In Solid Tumors \[RECIST\]
- Secondary Outcome Measures
Name Time Method Progression free survival (PFS) 5 years Patient characteristics 5 years Description of group differences between ERCC-1 low and ERCC-1 high patients with respect to KRAS status
Secondary resection rate 5 years Molecular markers for toxicity 5 years Number of adverse events during study treatment 5 years Response rate 5 years Description of group differences between ERCC-1 low and ERCC-1 high patients with respect to response rate, PFS and OS
Trial Locations
- Locations (11)
LKH Feldkirch, Interne E
🇦🇹Feldkirch, Vorarlberg, Austria
A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
🇦🇹Kufstein, Tirol, Austria
LKH Hohenems, Interne Intensivmedizin
🇦🇹Hohenems, Austria
Medizinische Universität Wien, Univ.Klinik für Innere Medizin I, Abteilung für Onkologie
🇦🇹Vienna, Austria
KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische Onkologie
🇦🇹Linz, Oberösterreich, Austria
Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum
🇦🇹Salzburg, Austria
LKH Bregenz
🇦🇹Bregenz, Austria
KH Dornbirn, Innere Medizin
🇦🇹Dornbirn, Austria
LKH Bludenz Innere Medizin
🇦🇹Bludenz, Austria
Universitätsklinikum Graz
🇦🇹Graz, Austria
Krankenhaus d. Barmherzigen Schwestern Linz
🇦🇹Linz, Austria